Tech Center 1600 • Art Units: 1658 1676
This examiner grants 50% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18227540 | GDF11 VARIANTS AND USES THEREOF | Non-Final OA | President and Fellows of Harvard College |
| 18361516 | Activatable Membrane-Interacting Peptides and Methods of Use | Non-Final OA | The Regents of the University of California |
| 18297593 | RECOMBINANTLY ENGINEERED POLYPEPTIDES CAPABLE OF RECYCLING NONCANONICAL COFACTORS | Non-Final OA | The Regents of the University of California |
| 16082924 | NANOLIPOPROTEIN PARTICLES AND RELATED COMPOSITIONS METHODS AND SYSTEMS FOR IMPROVED DRUG LOADING | Non-Final OA | The Regents Of The University of California |
| 17624824 | MULTISPECIFIC TRANSTHYRETIN IMMUNOGLOBULIN FUSIONS | Non-Final OA | AMGEN INC. |
| 18783546 | METHOD OF TREATING PATIENTS WITH HEPATORENAL SYNDROME TYPE 1 | Non-Final OA | Mallinckrodt Pharmaceuticals Ireland Limited |
| 17976606 | METHODS AND COMPOSITIONS FOR IMPROVING KIDNEY FUNCTION IN PATIENTS WITH HEPATORENAL SYNDROME | Final Rejection | Mallinckrodt Pharmaceuticals Ireland Limited |
| 17587442 | METHOD OF TREATING PATIENTS WITH HEPATORENAL SYNDROME TYPE 1 | Final Rejection | Mallinckrodt Pharmaceuticals Ireland Limited |
| 17340765 | METHOD OF TREATING PATIENTS WITH HEPATORENAL SYNDROME TYPE 1 | Final Rejection | Mallinckrodt Pharmaceuticals Ireland Limited |
| 18272092 | PEGYLATED P-SELECTIN INHIBITORS | Non-Final OA | Beth Israel Deaconess Medical Center, Inc. |
| 17793369 | PEGYLATED IGE-DEPENDENT HISTAMINE-RELEASING FACTOR (HRF)-BINDING PEPTIDE AND USE THEREOF | Final Rejection | EWHA UNIVERSITY - INDUSTRY COLLABORATION FOUNDATION |
| 17233022 | BULLFROG SKIN-DERIVED COLLAGEN, MATERIALS COMPRISING THEREOF, AND APPLICATIONS IN WOUND HEALING | Non-Final OA | Nanyang Technological University |
| 19018888 | iRGD-ANALOGS AND RELATED THERAPEUTIC METHODS | Non-Final OA | LISATA THERAPEUTICS, INC. |
| 17838030 | CYCLIC COMPOUNDS FOR TREATING CARDIOVASCULAR DISORDERS AND WOUNDS | Final Rejection | University of South Florida |
| 18815249 | REAGENTS AND METHODS FOR BIOORTHOGONAL LABELING OF BIOMOLECULES IN LIVING CELLS | Final Rejection | OREGON STATE UNIVERSITY |
| 18257165 | CELL PENETRATING PEPTIDE MEDIATED RNA TRANSDUCTION WITHIN INSECT CELLS | Non-Final OA | PIONEER HI-BRED INTERNATIONAL, INC. |
| 16963578 | USE OF CYCLIC PEPTIDES IN COSMETIC | Non-Final OA | Sederma |
| 16633701 | COMPOUND AND METHOD FOR PRODUCING THE SAME | Non-Final OA | PUSAN NATIONAL UNIVERSITY INDUSTRY-UNIVERSITY COOPERATION FOUNDATION |
| 18281147 | AFFINITY AGENTS | Non-Final OA | Avitide LLC |
| 17198285 | PEPTIDIC PROTEIN KINASE C INHIBITORS AND USES THEREOF | Final Rejection | UNIVERSITE DE GENEVE |
| 18352077 | COMPOSITIONS INCLUDING MULTI-AGONIST PEPTIDES AND METHODS OF MANUFACTURE AND USE | Non-Final OA | Pep2Tango Therapeutics Inc. |
| 18259752 | VEGF-REGULATING PEPTIDES | Non-Final OA | IDP DISCOVERY PHARMA, S.L. |
| 18256788 | USE OF MAIT CELLS FOR CONTROLLING GRAFT VERSUS HOST DISEASE | Non-Final OA | ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS |
| 18128465 | METHODS OF USING ACTIVIN RECEPTOR TYPE II VARIANTS | Non-Final OA | Keros Therapeutics, Inc. |
| 18170979 | HYDROGEL COMPOSITION AND ASSOCIATED METHOD OF USE | Final Rejection | Quthero, Inc. |
| 16337730 | NOVEL FORMULATIONS | Non-Final OA | Arecor Limited |
| 17767056 | A composition for boosting the immune system | Non-Final OA | MAOLAC LTD. |
| 17712752 | METHOD OF TREATING MELANOCORTIN-4 RECEPTOR PATHWAY-ASSOCIATED DISORDERS | Non-Final OA | RHYTHM PHARMACEUTICALS, INC. |
| 15764730 | METHOD OF TREATING MELANOCORTIN-4 RECEPTOR PATHWAY-ASSOCIATED DISORDERS | Non-Final OA | RHYTHM PHARMACEUTICALS, INC. |
| 17693478 | TREATMENT FOR TUMORS DRIVEN BY METABOLIC DYSFUCTION | Final Rejection | SynDevRx, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy